Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyloid beta
Biotech
FDA revises guidance on predicting Alzheimer's drug benefits
The FDA said amyloid reduction can be considered as a surrogate endpoint for predicting clinical benefit, according to newly revised draft guidelines.
Gabrielle Masson
Mar 12, 2024 7:40am
Alzheimer's transmission via procedure may boost prion theory
Jan 31, 2024 1:27pm
Roche’s Genentech returns Alzheimer’s assets to AC Immune
Jan 22, 2024 8:47am
Acumen posts early Alzheimer's data for next-gen Leqembi rival
Jul 17, 2023 5:32am
Roche nabs FDA nod for another pair of CSF tests for Alzheimer's
Jun 28, 2023 4:37pm
2022's 10 top clinical trial flops
Feb 21, 2023 3:00am